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Methods 
Synthesis of azidonorleucine-biotin (12): Azidonorleucine (12.65 mg, 0.073 mmol) 
and PFP-biotin (30.1 mg, 0.073 mmol) were dissolved in 1.5 mL of a 9:1:5 mixture of 
dimethylformamide, dimethylsulfoxide and methanol. Triethylamine (4 equiv) was ad-
ded and the reaction stirred overnight at room temperature. The reaction was purified 
on a C18 Sep-Pak column (Waters) using a stepwise gradient from 0.1% trifluoro-
acetic acid to 100% acetonitrile. The fractions containing the desired product were 
lyophilized to 6.8 mg of a fluffy white powder (23.4% yield). ESI MS (m/z): 398.9 
[M+H]+ (expected m/z: 398.17) 
Synthesis of Azido-PEG5000-Fluorescein (APF, 13): Azidopropylamine was syn-
thesized as previously described.1 To prepare the azide-functionalized PEG, mSPA-
PEG-fluorescein (29 mg, 6 µmol) was dissolved in azidopropylamine (300 µL, 2.9 
mmol) and allowed to react at room temperature for 2 h. The reaction mixture was 
then added dropwise to 20 mL of diethyl ether which caused the PEG reagents to 
form a yellow precipitate. The precipitate was collected by centrifugation and the 
ether supernatant decanted. The precipitate was dissolved in 1 mL of methanol and 
added dropwise to ether again and the precipitate collected as before. The reco-
vered precipitate was used without further purification. Addition of an azide was con-
firmed by IR analysis. 
Construction of Arg-eDHFR-HA and Gly eDHFR-HA plasmids: DNA fragments 
encoding the gene for E. coli dihydrofolate reductase were amplified by PCR from E. 
coli genomic DNA with the following pairs of primers: Oligo 298 (5’-AGGCTCCGCG-
GTGGTcgtAAAATGATCAGTCTGATTGCGGC–3’) and Oligo 314 (5’-TTTAAGCTT-
AGGCGTAATCTGGGACATCGTATGGGTAGCCGCTCCCCCGCCGCTCCAGAATC
T–3’) for Arg-eDHFR-HA; and Oligo 298 and Oligo 301 (5’-AGGCTCCGCGGTGGT-
ggtAAAATGATCAGTCTGATTGCGGC-3’) for Gly eDHFR-HA. The resulting frag-
ments were digested with SacII and HindIII, and ligated into SacII / HindIII-digested 
pHUE[2] to generate plasmids pKP141 and pKP144, respectively. 
Expression and purification of recombinant proteins: Overnight cultures in E. coli 
strain KPS17[3] were subcultured 1:100 into 200 mL Luria broth containing ampicillin 
and grown to a late exponential phase at 37°C. Protein expression was induced by 
adding isopropyl-1-thio-b-D-galactopyranoside (IPTG) to a final concentration of 0.1 
mM. After 3 h, harvested cells were resuspended in 15 mL of buffer L (50 mM Na2H-
PO4/NaH2PO4 at pH 7.4, 500 mM NaCl, 10 mM imidazole), with 1 mM phenylmethyl-
sulfonyl fluoride. His6-tagged recombinant proteins were purified by nickel-affinity 
chromatography using batch mode under native conditions, based on the QIAexpress  
protocol (Qiagen). The cells were lysed by sonication (3 x 1 min bursts at 0°C) and 
the soluble protein fraction recovered by centrifugation at 4°C  (15 min at 15 300 g). 
To the supernatant, 2 mL of a 50% slurry of nickel-nitrilotriacetic acid (Ni-NTA) aga-
rose in buffer L was added; the mixture was then placed on a rotary wheel at 4°C  for 
1 h. The lysate/Ni-NTA mixture was centrifuged (5 min at ~550g) and the remaining 
Ni-NTA agarose pellet was washed 5 times in 50 mL buffer W (50 mM Na2HPO4/ 
NaH2PO4 at pH 7.4, 500 mM NaCl, 30 mM imidazole). The His6-tagged protein was 
eluted from the Ni-NTA resin in 1 mL fractions with buffer L containing 300 mM imid-
azole. Chosen fractions were pooled and  dialyzed against buffer L, along with deubi-
quitylating protease Usp2-cc6 for 12 h at 4°C. After cleavage by the protease, nickel 
affinity chromatography was used to separate Usp2-cc and the His6-tagged ubiquitin 
domain from the modified DHFR according to published methods.[2] 
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Table S1. The percent of modified protein Etf-R-DHFR after increasing reaction 
length as determined by comparison of the molar amounts of arginine found by Ed-
man degradation in analyses of the first and second residues. Arginine found as the 
first residue arises from unmodified protein, whereas arginine found as the second 
residue arises from modified protein. The reaction is largely complete after 3 h.  
 
Incubation Time [h] Percent modification 
2 80 
3 92 
4 93 
 
 
 Figure S1. A) Representative reversed-phase HPLC analysis (UV detection at 324 nm) of 
the transfer of leucine to KA-AMC after incubation. A small amount of the starting material 
(a), and the tripeptide product, LKA-AMC, (b) are visible. B) The ESI mass spectrum of (b) 
confirms its identity as LKA-AMC, expected [MLKA-AMC+H]+=488.28 m/z and expected [MLKA-
AMC+2H]2+=244.6 m/z. C) MS/MS analysis of the singly charged ion of the product further 
confirms the N-terminal addition of leucine to KA-AMC with fragmentation into dipeptide LK, 
expected [MLK]+=242.19 m/z, tripeptide LKA, [MLKA]+=313.22 m/z, and the aminocoumarin, 
[Maminocoumarin+H]+=176.06 m/z. 
 
 
 
Figure S2. A) Representative reversed-phase HPLC analysis of the transfer reaction of tri-
fluoroleucine 2 (Tfl) to KA-AMC using UV detection at 324 nm. The starting material is not 
detectable at 17.5 min and the isomeric product (b) appears at 19.6 minutes. B) Analysis of 
peak (b) by ESI mass spectrometry confirms that it contains the tripeptide product, Tfl-KA-
AMC, expected [MTfl-KA-AMC+H]+ =542.25 m/z and [MTfl-KA-AMC+2H]2+ =271.67 m/z. C) MS/MS 
analysis of the singly charged ion of the product further confirms the N-terminal addition of Tfl 
to KA-AMC with fragmentation into dipeptide Tfl-K, expected [MTfl-K]+=296.16 m/z and the 
tripeptide Tfl-KA, expected [MTfl-KA]+=367.2 m/z. 
 
 
Figure S3. A) Representative reversed-phase HPLC analysis of the transfer reaction of de-
hydroleucine 1 (Ddl) to KA-AMC using UV detection at 324 nm. Both the starting material (a) 
and the tripeptide product (b) are visible. B) Analysis of peak (b) by ESI mass spectrometry 
confirms that it contains the tripeptide product, Ddl-KA-AMC, expecte [MDdl-KA-AMC+H]+ = 
486.26 m/z and expected[MDdl-KA-AMC+2H]2+ =243.63 m/z. C) MS/MS analysis of the singly 
charged ion of the product further confirms the N-terminal addition of Ddl to KA-AMC with 
fragmentation into dipeptide Ddl-K, [MDdl-K]+=240.17 m/z and the tripeptide Ddl-KA, [MDdl-KA]+= 
311.21 m/z. 
 
 
 
 
Figure S4. A) Representative reversed-phase HPLC analysis of the transfer reaction of oxo-
norvaline 3 (Oxo) to the dipeptide. Both the starting material (a) and the tripeptide product (b) 
are visible. B) The ESI mass spectra of peak (b) confirms that it contains the tripeptide-
aminocoumarin product, expected [MZxo-KA-AMC+H]+ = 488.24 m/z. C) Fragmentation of the tri-
peptide-AMC product ion results in production of the tripeptide ion, Oxo-KA, expected [MOxo-
KA]+=312.19 m/z, as well as loss of water, m/z = 470, and ammonium, m/z = 453 from the 
parent ion at 488.12 m/z. 
 
 
Figure S5. A) Representative reversed-phase HPLC analysis of the transfer reaction of p-
ethynylphenylalanine 5 (Etf) to KA-AMC using UV detection at 324 nm. Only the tripeptide 
product (b) are visible. B) Analysis of peak (b) by ESI mass spectrometry confirms that it 
contains the tripeptide product, Etf-KA-AMC, expected [MEtf -KA-AMC+H]+ =546.26 m/z and [MEtf -
KA-AMC+2H]2+ = 273.63 m/z. C) MS/MS analysis of the singly charged ion of the product further 
confirms the N-terminal addition of Etf to KA-AMC with fragmentation into dipeptide Etf-K, 
expected [MEtf -K]+=300.17 m/z and the tripeptide Etf-KA, [MEtf -KA]+= 371.45 m/z. 
 
 
 
Figure S6. A) Representative reversed-phase HPLC analysis of the addition reaction of p-
azidophenylalanine 4 (Azf) with detection at 324 nm. The retention time of the substrate peak 
(a) is indicated at 13.5 min. The identity of the product peak (b), Azf-KA-AMC, was verified by 
ESI MS. B) Analysis of peak (b) by ESI mass spectrometry confirms that it contains the tri-
peptide product, Azf-KA-AMC, expected [MAzf -KA-AMC+H]+ =563.27 m/z. C) MS/MS analysis of 
the singly charged ion of the tripeptide product leads to the loss of dinitrogen from daughter 
ion Azf-K, expected [Mamino-FK+H]+=289.18 m/z. 
 
 
Figure S7. A) Representative reversed-phase HPLC analysis of the transfer reaction of p-
cyanophenylalanine 6 (Cnf) to KA-AMC using UV detection at 324 nm. Both the starting 
material (a) and the tripeptide product (b) are visible. B) Analysis of peak (b) by ESI mass 
spectrometry confirms that it contains the tripeptide product, Cnf-KA-AMC, expected [MCnf -KA-
AMC+H]+ = 547.26 m/z and [MCnf -KA-AMC+2H]2+ =274.23 m/z. C) MS/MS analysis of the singly 
charged ion of the product further confirms the N-terminal addition of Cnf to KA-AMC with 
fragmentation into dipeptide Cnf-K, expected [MCnf -K]+=301.17 m/z and the tripeptide Cnf-KA, 
expected [MCnf -KA]+= 372.2 m/z. 
 
 
 
Figure S8. A) Representative reversed-phase HPLC analysis of the transfer reaction of p-
acetylphenylalanine 7 (Acf) to KA-AMC using UV detection at 324 nm. Both the starting 
material (a) and the tripeptide product (b) are visible. B) Analysis of peak (b) by ESI mass 
spectrometry confirms that it contains the tripeptide product, Acf-KA-AMC, expected [MAcf -KA-
AMC+H]+ =564.27 m/z and [MAcf -KA-AMC+2H]2+ =282.64 m/z. C) MS/MS analysis of the singly 
charged ion of the product further confirms the N-terminal addition of Acf to KA-AMC with 
fragmentation into dipeptide Acf-K, [MDdl-K]+=318.18 m/z and the tripeptide Acf-KA, [MAcf -KA]+= 
389.22 m/z. 
 
 
 
 
Figure S9. A) Representative reversed-phase HPLC analysis of the transfer reaction of azi-
dohomoalanine 8 (Aha) to KA-AMC using UV detection at 324 nm. Both the starting material 
(a) and the tripeptide product (b) are visible. B) Analysis of peak (b) by ESI mass spectrom-
etry confirms that it contains the tripeptide product, Aha-KA-AMC, expected [MAha-KA-AMC+H]+ = 
501.25 m/z and [MAha-KA-AMC+2H]2+ =251.13 m/z. C) MS/MS analysis of the singly charged ion 
of the product further confirms the N-terminal addition of Aha to KA-AMC with fragmentation 
into dipeptide Aha-K, [MAha-K]+=255.30 m/z and the tripeptide Aha-KA, [MAha-KA]+= 326.19 m/z. 
 
 
 
Figure S10. A) Representative reversed-phase HPLC analysis of the transfer reaction of 
homopropargylglycine 9 (Hpg) to KA-AMC using UV detection at 324 nm. Both the starting 
material (a) and the tripeptide product (b) are visible. B) Analysis of peak (b) by ESI mass 
spectrometry confirms that it contains the tripeptide product, Hpg-KA-AMC, expected [MHpg-
KA-AMC+H]+=484.25 m/z and [MHpg-KA-AMC+2H]2+ =242.63 m/z. C) MS/MS analysis of the singly 
charged ion of the product further confirms the N-terminal addition of Hpg to KA-AMC with 
fragmentation into dipeptide Hpg-K, expected [MHpg-K]+=238.16 m/z and the tripeptide Hpg-
KA, expected [MHpg-KA]+= 309.19 m/z. 
 
 
 
 
Figure S11. A) Representative Reversed-phase HPLC analysis of the transfer reaction of 
azidonorleucine 10 (Anl) to KA-AMC using UV detection at 324 nm. Both the starting material 
(a) and the tripeptide product (b) are visible. B) Analysis of peak (b) by ESI mass spectrom-
etry confirms that it contains the tripeptide product, Anl-KA-AMC, expected [MAnl-KA-AMC+H]+ = 
529.28 m/z and [MAnl-KA-AMC+2H]2+ = 265.14 m/z. C) MS/MS analysis of the singly charged ion 
of the product further confirms the N-terminal addition of Anl to KA-AMC with fragmentation 
into dipeptide Anl-K, expected [MAnl-K]+=283.19 m/z and the tripeptide Anl-KA, expected [MAnl-
KA]+= 354.23 m/z. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S12. Analysis of the first residue of Etf-R-eDHFR by Edman degradation after A) 2 h, 
B) 3 h, and C) 4 h. The peak labeled “R” arises from unmodified protein while the “Etf” peak 
arises from modified protein. 
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